









Markets
/
Stocks
/
nasdaq-hln
/

Haleon PLC

HLN

10.415USD

+0.115+1.12%

Market hours （ET）Quotes delayed by 15 min

93.58BMarket Cap

42.55P/E TTM



Haleon PLC

10.415

+0.115+1.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Haleon PLC

Currency: USD Updated: 2026-01-29

Key Insights

Haleon PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.79.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Haleon PLC's Score

Industry at a Glance

Industry Ranking

48 / 159

Overall Ranking

132 / 4540

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Haleon PLC Highlights

StrengthsRisks

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 8.92B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.

Undervalued

The company’s latest PE is 42.08, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 543.06M shares, decreasing 6.66% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 14.08K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.792

Target Price

+3.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Haleon PLC is 8.65, ranking 48 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.65

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Haleon PLC's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Haleon PLC is 4.63, ranking 156 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 42.08, which is 170.90% below the recent high of 114.00 and 15.34% above the recent low of 35.63.

Score

Industry at a Glance

Previous score

4.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Haleon PLC is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 11.50, with a high of 13.44 and a low of 5.88.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.792

Target Price

+3.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Haleon PLC

HLN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Haleon PLC is 8.91, ranking 37 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 10.68 and the support level at 9.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.90

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.045

Buy

RSI(14)

58.589

Neutral

STOCH(KDJ)(9,3,3)

72.616

Neutral

ATR(14)

0.181

Low Volatility

CCI(14)

56.424

Neutral

Williams %R

31.395

Buy

TRIX(12,20)

0.176

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.372

Buy

MA10

10.216

Buy

MA20

10.111

Buy

MA50

9.891

Buy

MA100

9.584

Buy

MA200

9.911

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Haleon PLC is 3.00, ranking 94 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 12.19%, representing a quarter-over-quarter decrease of 4.76%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 154.38M shares, representing 3.47% of shares outstanding, with 7.78% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

154.38M

-0.70%

Fidelity Management & Research Company LLC

89.11M

-8.62%

ClearBridge Investments, LLC

33.35M

+6.05%

Harding Loevner LP

17.91M

-20.58%

Wellington Management Company, LLP

15.68M

+18.70%

Fidelity Institutional Asset Management

14.89M

+4.58%

Sculptor Capital Management, Inc

9.95M

Managed Account Advisors LLC

9.04M

-17.67%

Aristotle Capital Management, LLC

8.06M

-1.64%

Altshuler Shaham Ltd.

7.94M

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Haleon PLC is 9.95, ranking 1 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.